Race Oncology Investor Presentation 2024

Race Oncology is developing Bisantrene, a clinically proven anticancer drug with ~80% success rate, designed to address cardiotoxicity from chemotherapy. The company targets a market of 20 million anthracycline doses annually with potential sales exceeding US$5 billion, leveraging FDA accelerated approval pathways for rapid commercialization.